Evommune Inc (EVMN)

$23.56 -0.69 (-2.85%)
Market Cap 812.21M
Revenue (ttm) 13.00M
Net Income (ttm) -68.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -529.77%
Debt to Equity Ratio 0.00
Volume 1,043,400
Avg Vol 413,688
Day's Range N/A - N/A
Shares Out 36.02M
Stochastic %K 66%
Beta N/A
Analysts Strong Sell
Price Target $52.00

Company Profile

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 925 247 4481
Address:
1841 Page Mill Road, Suite 100, Palo Alto, United States
buythedipsisay
buythedipsisay Jun. 24 at 6:33 PM
$EVMN don’t like this dip
0 · Reply
buythedipsisay
buythedipsisay Jun. 24 at 5:11 PM
$EVMN wait for the ah spike - then we will know it’s coming tomorrow.
0 · Reply
buythedipsisay
buythedipsisay Jun. 23 at 9:35 PM
$EVMN 7 days left in June… they updated their timing in may. No reason why they would have cut it that close and not left it as 1h 26 if it wasn’t gunna be released. Think we hear Thursday
0 · Reply
laaarsas
laaarsas Jun. 23 at 10:45 AM
$EVMN No dat this week?
0 · Reply
Monkey7779192
Monkey7779192 Jun. 22 at 10:45 PM
$EVMN Will short this if no data till Friday.
1 · Reply
Timefortendies77
Timefortendies77 Jun. 22 at 10:26 PM
$EVMN Sold out of this awhile back, but still rooting for the company. Don't like the wide spreads and dead options but I like their drug and think it has big potential.
0 · Reply
explover
explover Jun. 22 at 9:15 PM
$EVMN huge short interest, stars holding massive positions - RA Capital, Baker Bros, Perceptive Advisors, you name it. Even some options OI, total exposure >1.5x daily volume. A placebo-controlled phase 2b in CSU is quite a bit harder than an open-label phase 2a in CIndU, but the signal observed is alluring enough to paint prospects of an oral small molecule with a novel mechanism of action challenging biologics in mast-cell-mediated dermatology. In case of clean safety UAS7 stat. sig. and UAS7 CR>20% - could surely challenge biologics with the stock appreciating vigorously to the tune of ~+50% with CR=20% and +100%-150% with CR>30%. A serious enough safety signal would drop the SP closer to cash, efficacy miss would drop the SP as well, but there is AD later this year.
1 · Reply
laaarsas
laaarsas Jun. 20 at 7:20 PM
$EVMN Hmm when data…
0 · Reply
Robby83
Robby83 Jun. 17 at 5:45 PM
$EVMN every time there's a huge gap in a chart... Would be nice to close it and get moving back upward.
0 · Reply
TheRealiSwag
TheRealiSwag Jun. 17 at 2:19 PM
$VSTM just a few days away from potentially steamrolling 25% short of the float on data. After getting cut down from $11 to under $4 in 8 months, its time to cover as the smart business practice takes over from here. High risk/high reward here folks. Also watching $EVMN for data any day now, one of Bairds leading candidates for M&A targets this year fwiw. $ELVN has been best in class following TERN before they were taken out. $XBI keep the momentum intact!
0 · Reply
Latest News on EVMN
Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

2026-06-22T21:55:09.000Z - 2 days ago

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

ABBV APGE

Evommune Transcript: AGM 2026

Jun 2, 2026, 11:30 AM EDT - 22 days ago

Evommune Transcript: AGM 2026

Evommune price target raised to $55 from $54 at Morgan Stanley

2026-05-11T15:52:55.000Z - 6 weeks ago

Evommune price target raised to $55 from $54 at Morgan Stanley

Evommune reports Q1 EPS (64c), consensus (71c)

2026-05-07T22:50:50.000Z - 6 weeks ago

Evommune reports Q1 EPS (64c), consensus (71c)

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

May 7, 2026, 4:05 PM EDT - 6 weeks ago

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Evommune Quarterly report: Q1 2026

Evommune Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Evommune Earnings release: Q1 2026

Evommune Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Evommune Slides: Corporate presentation

Evommune initiated with a Buy at Stifel

2026-04-30T20:39:05.000Z - 7 weeks ago

Evommune initiated with a Buy at Stifel

Evommune Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Evommune Proxy statement: Proxy filing

Evommune Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Evommune Proxy statement: Proxy filing

Evommune Registration statement: Registration filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Evommune Registration statement: Registration filing

Evommune Transcript: Status update

Apr 13, 2026, 2:00 PM EDT - 2 months ago

Evommune Transcript: Status update

Evommune assumed with an Outperform at Oppenheimer

2026-04-07T14:18:01.000Z - 2 months ago

Evommune assumed with an Outperform at Oppenheimer

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Apr 6, 2026, 9:00 AM EDT - 2 months ago

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Evommune price target lowered to $50 from $65 at H.C. Wainwright

2026-03-18T10:12:14.000Z - 3 months ago

Evommune price target lowered to $50 from $65 at H.C. Wainwright

Evommune initiated with a Buy at Clear Street

2026-03-17T20:25:28.000Z - 3 months ago

Evommune initiated with a Buy at Clear Street

Evommune initiated with an Outperform at RBC Capital

2026-03-10T10:11:40.000Z - 3 months ago

Evommune initiated with an Outperform at RBC Capital

Evommune reports Q4 EPS ($1.43), consensus (84c)

2026-03-05T21:06:11.000Z - 3 months ago

Evommune reports Q4 EPS ($1.43), consensus (84c)

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Mar 5, 2026, 4:01 PM EST - 3 months ago

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Evommune Earnings release: Q4 2025

Mar 5, 2026, 7:00 AM EST - 3 months ago

Evommune Earnings release: Q4 2025

Evommune Annual report: Q4 2025

Mar 5, 2026, 7:00 AM EST - 3 months ago

Evommune Annual report: Q4 2025

Evommune Slides: Corporate presentation

Mar 5, 2026, 7:00 AM EST - 3 months ago

Evommune Slides: Corporate presentation

Evommune price target raised to $54 from $36 at Morgan Stanley

2026-02-18T18:20:32.000Z - 4 months ago

Evommune price target raised to $54 from $36 at Morgan Stanley

Evommune announces $125M private placement

2026-02-13T01:35:10.000Z - 4 months ago

Evommune announces $125M private placement

Evommune Announces $125 Million Private Placement

Feb 12, 2026, 8:30 PM EST - 4 months ago

Evommune Announces $125 Million Private Placement

Evommune price target raised to $55 from $40 at Evercore ISI

2026-02-10T18:36:15.000Z - 4 months ago

Evommune price target raised to $55 from $40 at Evercore ISI

Evommune price target raised to $65 from $35 at H.C. Wainwright

2026-02-10T17:55:11.000Z - 4 months ago

Evommune price target raised to $65 from $35 at H.C. Wainwright

Evommune jumps 67% to $28.13 after atopic dermatitis data

2026-02-10T13:37:36.000Z - 4 months ago

Evommune jumps 67% to $28.13 after atopic dermatitis data

Evommune Transcript: Study result

Feb 10, 2026, 8:30 AM EST - 4 months ago

Evommune Transcript: Study result

Evommune Press release: Study result

Feb 10, 2026, 8:30 AM EST - 4 months ago

Evommune Press release: Study result

Evommune Slides: Study result

Feb 10, 2026, 8:30 AM EST - 4 months ago

Evommune Slides: Study result

Evommune reports EVO301 trial met primary endpoint

2026-02-10T12:40:58.000Z - 4 months ago

Evommune reports EVO301 trial met primary endpoint

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

Feb 10, 2026, 7:30 AM EST - 4 months ago

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

Evommune Slides: Corporate presentation

Jan 7, 2026, 7:00 AM EST - 6 months ago

Evommune Slides: Corporate presentation

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

Dec 11, 2025, 4:05 PM EST - 6 months ago

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

Evommune Quarterly report: Q3 2025

Dec 11, 2025, 4:00 PM EST - 6 months ago

Evommune Quarterly report: Q3 2025

Evommune Earnings release: Q3 2025

Dec 11, 2025, 4:00 PM EST - 6 months ago

Evommune Earnings release: Q3 2025

Evommune Slides: Corporate Presentation

Dec 11, 2025, 4:00 PM EST - 6 months ago

Evommune Slides: Corporate Presentation

Evommune Announces Pricing of its Initial Public Offering

Nov 5, 2025, 7:45 PM EST - 8 months ago

Evommune Announces Pricing of its Initial Public Offering

Evommune Announces Commencement of Initial Public Offering

Oct 30, 2025, 6:30 AM EDT - 8 months ago

Evommune Announces Commencement of Initial Public Offering

Evommune Registration statement: Registration Filing

Oct 17, 2025, 8:00 AM EDT - 8 months ago

Evommune Registration statement: Registration Filing

Evommune files for IPO to advance immune drug work

Oct 10, 2025, 8:31 AM EDT - 9 months ago

Evommune files for IPO to advance immune drug work

Evommune IPO Registration Document (S-1)

Oct 9, 2025, 2:18 PM EDT - 9 months ago

Evommune IPO Registration Document (S-1)

Chronic inflammatory disease biotech Evommune files for a $100 million IPO

Oct 9, 2025, 10:32 AM EDT - 9 months ago

Chronic inflammatory disease biotech Evommune files for a $100 million IPO

buythedipsisay
buythedipsisay Jun. 24 at 6:33 PM
$EVMN don’t like this dip
0 · Reply
buythedipsisay
buythedipsisay Jun. 24 at 5:11 PM
$EVMN wait for the ah spike - then we will know it’s coming tomorrow.
0 · Reply
buythedipsisay
buythedipsisay Jun. 23 at 9:35 PM
$EVMN 7 days left in June… they updated their timing in may. No reason why they would have cut it that close and not left it as 1h 26 if it wasn’t gunna be released. Think we hear Thursday
0 · Reply
laaarsas
laaarsas Jun. 23 at 10:45 AM
$EVMN No dat this week?
0 · Reply
Monkey7779192
Monkey7779192 Jun. 22 at 10:45 PM
$EVMN Will short this if no data till Friday.
1 · Reply
Timefortendies77
Timefortendies77 Jun. 22 at 10:26 PM
$EVMN Sold out of this awhile back, but still rooting for the company. Don't like the wide spreads and dead options but I like their drug and think it has big potential.
0 · Reply
explover
explover Jun. 22 at 9:15 PM
$EVMN huge short interest, stars holding massive positions - RA Capital, Baker Bros, Perceptive Advisors, you name it. Even some options OI, total exposure >1.5x daily volume. A placebo-controlled phase 2b in CSU is quite a bit harder than an open-label phase 2a in CIndU, but the signal observed is alluring enough to paint prospects of an oral small molecule with a novel mechanism of action challenging biologics in mast-cell-mediated dermatology. In case of clean safety UAS7 stat. sig. and UAS7 CR>20% - could surely challenge biologics with the stock appreciating vigorously to the tune of ~+50% with CR=20% and +100%-150% with CR>30%. A serious enough safety signal would drop the SP closer to cash, efficacy miss would drop the SP as well, but there is AD later this year.
1 · Reply
laaarsas
laaarsas Jun. 20 at 7:20 PM
$EVMN Hmm when data…
0 · Reply
Robby83
Robby83 Jun. 17 at 5:45 PM
$EVMN every time there's a huge gap in a chart... Would be nice to close it and get moving back upward.
0 · Reply
TheRealiSwag
TheRealiSwag Jun. 17 at 2:19 PM
$VSTM just a few days away from potentially steamrolling 25% short of the float on data. After getting cut down from $11 to under $4 in 8 months, its time to cover as the smart business practice takes over from here. High risk/high reward here folks. Also watching $EVMN for data any day now, one of Bairds leading candidates for M&A targets this year fwiw. $ELVN has been best in class following TERN before they were taken out. $XBI keep the momentum intact!
0 · Reply
buythedipsisay
buythedipsisay Jun. 15 at 11:57 PM
$EVMN and $CNTB The race for results. Who will be the first mid summer data dropper?!?
1 · Reply
Monkey7779192
Monkey7779192 Jun. 15 at 12:00 AM
$EVMN Might put a short bet here if no data Friday this week.
1 · Reply
TheRealiSwag
TheRealiSwag Jun. 12 at 4:49 PM
$EVMN folks better leave some dry powder aftwr this gets cut in half and Tutes buy more hand over fist in the low teens. Very early stages here fwiw
1 · Reply
Monkey7779192
Monkey7779192 Jun. 11 at 12:41 AM
$EVMN Likelihood of poor data?
1 · Reply
ParallelPort
ParallelPort Jun. 7 at 2:05 PM
$EVMN The scientific trail we’ve been waiting for is officially rolling out, and Evommune used the American Headache Society (AHS) Annual Scientific Meeting this weekend to lay out the concrete biological foundation for its next major clinical campaign. Here is the breakdown of the newly highlighted science, the upcoming trial, and why this is highly relevant. Evommune presented a translational data poster focused on their lead molecule, EVO756 (the same oral drug behind Tuesday's hives readout). The data specifically mapped out the pivotal role of a receptor called MRGPRX2 in the brain's pain networks. The study visually and biologically demonstrated how MRGPRX2 acts as a central link between two key components: Meningeal Mast Cells: Inflammatory cells in the protective layers of the brain. Trigeminal Neurons: The primary sensory nerve pathways responsible for transmitting severe migraine pain.
1 · Reply
ParallelPort
ParallelPort Jun. 7 at 2:04 PM
$EVMN By using EVO756 to block this MRGPRX2 pathway, Evommune proved they can disrupt this neuroimmune interaction—essentially blocking the "itch and pain" signals at the source before they can trigger a full-scale migraine attack. This presentation was the formal scientific springboard for a brand-new indication. Evommune confirmed that it is building directly on this data to launch a major new clinical program: The Indication: Migraine Prophylaxis (the preventative treatment of chronic migraines). The Trial Phase: A Phase 2b dose-ranging clinical trial. The Timeline: Scheduled to officially initiate in mid-2026 (which means the protocol is being finalized right now to launch this summer). Right now, the preventative migraine market is dominated by injectable biologics (like CGRP inhibitors). By entering this space with EVO756, Evommune is gunning for a holy grail in neurology: a once-daily, highly effective oral pill that stops migraines before they start, with zero injection burden.
0 · Reply
ParallelPort
ParallelPort Jun. 7 at 2:03 PM
$EVMN This update officially transforms Evommune from a pure "skin and allergy" biotech into a highly diversified, multi-therapeutic powerhouse. The market has been completely ignoring the neuro-inflammation/migraine pipeline, pricing EVMN almost entirely on its hives data. This new trial pipeline injects a massive wave of unpriced fundamental value into the stock right as the primary catalysts hit the tape:
0 · Reply
ParallelPort
ParallelPort Jun. 7 at 4:46 AM
$EVMN Big news Saturday, if you don't know about it already i will post details tomorrow.
3 · Reply
ParallelPort
ParallelPort Jun. 4 at 1:14 AM
$EVMN Disregard the last post👇 After reading through all these transactons were pursuant to rule 10b5-1 and all these sells were set up in march.👍
1 · Reply
ParallelPort
ParallelPort Jun. 4 at 12:59 AM
$EVMN Looks like EVMN executives selling hand over fist.... to be positive on a stock this is not good. This thing might get crushed tomorrow.
1 · Reply
ParallelPort
ParallelPort Jun. 3 at 4:04 PM
$EVMN Wed. 12.00 pm. 45,000 volume...240 sell--1,267 buys and over 43,000 neutral. Am i worried about this price movement...not at all. If it were heavy selling then yes, but it's not. Just algos pulling triggers.
0 · Reply
Timefortendies77
Timefortendies77 Jun. 2 at 1:57 PM
$EVMN Data coming this month
0 · Reply